Loading organizations...
§ Private Profile · Munich, Bayern, Germany
Tubulis is a technology company.
Tubulis has raised $575.0M across 4 funding rounds.
Key people at Tubulis.
Tubulis has raised $575.0M in total across 4 funding rounds.
Tubulis develops next-generation antibody-drug conjugates (ADCs) using its proprietary P5 conjugation, Tubutecan, and Alco5 platforms. These technologies enable the creation of ultra-stable ADCs with high drug-to-antibody ratios, improved biophysical properties, and optimized on-target delivery, while reducing off-target toxicity. The approach allows for the stable conjugation of various cytotoxins and protein degraders, aiming for highly differentiated therapeutic options primarily within oncology.
The company was co-founded in 2018 by Dr. Dominik Schumacher, serving as CEO, and Dr. Jonas Helma-Smets, CSO. Dr. Schumacher brought experience from the Leibniz-Forschungsinstitut and Ludwig Maximillian University (LMU) in Munich, while Dr. Helma-Smets, also from LMU, contributed his background in biotechnology and antibody engineering, having previously co-founded ChromoTek GmbH. Their combined scientific and entrepreneurial expertise drove the establishment of Tubulis to advance targeted therapeutics.
Tubulis's products are designed to benefit cancer patients by providing more effective and durable treatment options. The company's vision is to become a leader in targeted therapeutics, translating deep scientific understanding into meaningful clinical benefits. They aim to broaden the therapeutic horizon in oncology through their innovative ADC pipeline, continuously seeking to improve patient outcomes.
Tubulis is a biotechnology company developing antibody-drug conjugates (ADCs) for solid and hematologic tumors, focusing on improved on-tumor delivery and anti-tumor activity through proprietary conjugation technologies.[1][6] It builds advanced ADCs like TUB-040 (targeting NaPi2b for platinum-resistant ovarian cancer and non-small cell lung cancer) and TUB-030 (targeting 5T4 for solid tumors), serving oncology patients and partners such as Bristol Myers Squibb and Gilead Sciences by solving issues like payload instability, off-target toxicity, and resistance in existing ADCs.[2][4][5] Founded in 2020 and based in Planegg-Martinsried, Germany, Tubulis has raised over $575 million across rounds, including a $361 million Series C in 2025, fueling Phase 1/2 trials and preclinical expansion with strong growth momentum evidenced by clinical advancements and partnerships.[1][2]
Tubulis spun out from two German research institutes in 2020, leveraging expertise in protein-drug conjugates to address limitations in ADC design.[2][1] The founding team, led by CEO Dominik Schumacher, emerged from academic and biotech backgrounds focused on tailoring ADC components—such as linkers and payloads—to specific cancers, driven by the need for better tumor targeting amid rising ADC interest.[2] Early traction came from proprietary platforms like Tubutecan and P5 conjugation, leading to rapid patent filings (7 total, covering experimental cancer drugs) and partnerships; a pivotal moment was advancing multiple programs into clinics, including a Bristol Myers Squibb-licensed ADC entering human testing.[1][4][5]
Tubulis stands out in the ADC field through its integrated platforms enabling "uniquely matched" conjugates with superior stability and efficacy:
Tubulis rides the explosive ADC trend, where these "smart bombs" combine antibodies with cytotoxins to precisely kill cancer cells, fueled by approvals like Enhertu and market projections exceeding $20 billion by 2030.[2] Timing is ideal post-2020 spinout amid Big Pharma's ADC frenzy—partnerships with Bristol Myers Squibb and Gilead validate its platforms while Series C funding aligns with clinical readouts.[1][2][5] Favorable forces include advancing topoisomerase-I inhibitors (e.g., Exatecan, SN38) beyond first-gen limitations like instability and resistance, plus novel degraders for new mechanisms.[4] Tubulis influences the ecosystem by licensing tech (e.g., Tubutecan to Bristol Myers) and preempting resistance in ADC-exposed patients, accelerating precision oncology innovation from Europe.[2]
Tubulis is primed for ADC leadership with TUB-040's Phase 1/2 data at ESMO 2025 potentially catalyzing Phase 3 advancement, alongside TUB-030 readouts and preclinical escalations like degraders.[2][5] Trends like combination therapies, resistance-busting payloads, and AI-optimized conjugates will shape its path, bolstered by $575M+ war chest for scaling manufacturing and trials.[1][2] Its influence may evolve into a platform licensor for Big Pharma, expanding beyond proprietaries to dominate next-gen ADCs—echoing its origin as a spinout innovator now delivering durable tumor-killing precision.
Key people at Tubulis.
Tubulis has raised $575.0M in total across 4 funding rounds.
Tubulis's investors include Venrock, 5AM Ventures, Abingworth, Andera Partners, Coparion, EQT Life Sciences, Frazier Healthcare Partners, Hakan Goker, Third Rock Ventures, Versant Ventures, Lorence Kim, Bayern Kapital.
Tubulis has raised $575.0M across 4 funding rounds. Most recently, it raised $360.0M Series C in October 2025.
